Table 1.
LncRNA | Type of cancer | Mechanism | Function | Immune checkpoints | References |
---|---|---|---|---|---|
LncMX1-215 | HNSCC | Interrupting H3K27 acetylation | Inhibit proliferation and invasion | Downregulate PD-L1 | [79] |
SNHG14 | Nasopharyngeal carcinoma | Sponge miR-5590-3p | Promote EMT | Upregulate PD-L1 | [80] |
IFITM4P | OSCC cytoplasm | recruit SASH1, increase NF-κB phosphorylation | Oral carcinogenesis | Upregulate PD-L1 | [82] |
OSCC nucleus | reduce PTEN transcription | ||||
CRNDE | OSCC | Sponge miR-545-5p | CD8 + T-cell exhaustion | Upregulate TIM3 | [83] |
PD-L1-lnc | LUAD | Enhancing c-Myc transcriptional activity | Increases proliferation and invasion | [89] | |
C5orf64 | LUAD | NA | TME modulation | Upregulate PD-1, PD-L1 and CTLA-4 | [88] |
MALAT1 | LUAD | Sponge miR-200a-3p | Increases proliferation and invasion | Upregulate PD-L1 | [93] |
CASC11 | HCC | Activation of NF-κB and PI3K/AKT/mTOR pathway | Promote proliferation, mobility, and glucose metabolism | Upregulate PD-L1 | [95] |
SNHG3 | HCC | Sponge miR-214-3p | Immune cell infiltration | Upregulate PD-L1 | [97] |
Ac099850.3 | HCC | Target PRR11/PI3K/AKT pathway | Promote proliferation and invasion | Upregulate PD-1, PD-L1, PD-L2, and CTLA4 | [98] |
PCED1B-AS1 | HCC | Sponge miR-194-5p | Induce PD-Ls-mediated immunosuppression | ipregulate PD-L1, PD-L2 | [99] |
MIAT | HCC | NA | Promote immune escape | Upregulate PD-1, PD-L1, and CTLA4 | [96] |
RP11-424C20.2 | HCC | Sponge miR-378a-3p | Regulate immune infiltration | [100] | |
KCNQ1OT1 | HCC | Sponge miR-506 | Contribute immune escape | Upregulate PD-L1 | [101] |
ANRIL | HCC | Target miR-203 | Decrease the percentages of NK cells and T cells | [102] | |
NEAT1 | HCC | Sponge miR-155 | Inhibit the antitumor activity of CD8 + T cell | Upregulate TIM | [103] |
LINK-A | TNBC | Enhance degradation of the PLC, Rb and p53 | Downregulate cancer cell antigen presentation and intrinsic tumor suppression | [107] | |
GATA3-AS1 | TNBC | Sponge miR-676-3p | Inhibit PD-L1 ubiquitination | Upregulate PD-L1 | [108] |
NKILA | Breast cancer | Inhibiting NF-κB activity | Sensitize T cells to activation-induced cell death | [110] | |
FENDRR |
Breast cancer And CRC |
Enhance the inflammatory and WNT signaling pathways | Immune activation | [111] | |
TM4F1-AS1 | Stomach adenocarcinoma | NA | Decrease proportion of CD8 + T cells | [113] | |
SNHG15 | Stomach adenocarcinoma | Sponge miR141 | Promote immune escape | Upregulate PD-L1 | [114] |
MIR17HG | CRC | Sponge miR-375, decrease NF-κB/RELA expression | Promote metastasis | [37] | |
SNHG29 | CRC | Degradation of YAP protein | Promotes anti-tumor immunity | Upregulate PD-L1 | [118] |
LINC00657 | CRC | Sponge miR1224-3p and miR-338-5p | Impair the cytotoxicity of CD8 + T cells | [119] | |
LINC00657 | CRC | Sponge miR-203a | Promotion of stem cell-like cell invasion ability | [120] | |
NEAT1 | GBM | Induce NF-κB signal pathway | Promoted immune escape | Upregulate PD-L1 | [123] |
PCAT6 | CCA | Sponge miR-326 | Induce the accumulation of ROS, mitochondria and metabolic dysfunction in macrophages | [124] |